Wolfgang Brück Selected Research

Demyelinating Diseases (Demyelinating Disease)

1/2021	Iron Heterogeneity in Early Active Multiple Sclerosis Lesions.
1/2021	Magnetic Resonance Imaging Correlates of Multiple Sclerosis Immunopathological Patterns.
10/2020	Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
1/2020	Antibody signatures in patients with histopathologically defined multiple sclerosis patterns.
1/2020	Extensive subpial cortical demyelination is specific to multiple sclerosis.
1/2019	NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies.
1/2019	OTUB1 inhibits CNS autoimmunity by preventing IFN-γ-induced hyperactivation of astrocytes.
1/2019	Microglia damage precedes major myelin breakdown in X-linked adrenoleukodystrophy and metachromatic leukodystrophy.
1/2019	Glial fibrillary acidic protein expression alters astrocytic chemokine release and protects mice from cuprizone-induced demyelination.
1/2018	Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Brück Research Topics

Disease

68	Multiple Sclerosis 01/2022 - 01/2002
47	Demyelinating Diseases (Demyelinating Disease) 01/2021 - 09/2005
21	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020 - 10/2002
18	Inflammation (Inflammations) 11/2021 - 10/2002
16	Infections 01/2022 - 08/2003
8	Progressive Multifocal Leukoencephalopathy 11/2021 - 02/2012
6	Neuromyelitis Optica (Devic's Disease) 01/2020 - 04/2014
6	Meningitis 01/2020 - 01/2002
6	Neoplasms (Cancer) 02/2019 - 03/2006
6	Disease Progression 01/2019 - 10/2002
5	Hypoxia (Hypoxemia) 01/2021 - 01/2003
5	Encephalitis (Encephalitis, Rasmussen) 10/2019 - 08/2014
5	Relapsing-Remitting Multiple Sclerosis 01/2019 - 12/2008
5	Neuroinflammatory Diseases 01/2019 - 10/2008
5	Bacterial Meningitis 12/2014 - 01/2002
4	Atrophy 01/2020 - 05/2012
4	Wallerian Degeneration 01/2017 - 01/2004
3	Glioma (Gliomas) 01/2020 - 10/2016
3	Brain Diseases (Brain Disorder) 01/2017 - 01/2003
3	Sepsis (Septicemia) 01/2017 - 07/2003
3	Autoimmune Diseases (Autoimmune Disease) 01/2016 - 10/2008
3	Immune Reconstitution Inflammatory Syndrome 03/2015 - 02/2012
3	Necrosis 12/2012 - 01/2002
2	Stroke (Strokes) 01/2020 - 01/2003
2	Meningoencephalitis 01/2020 - 10/2019
2	Central Nervous System Diseases (CNS Diseases) 01/2020 - 04/2011
2	Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked) 01/2019 - 01/2019
2	Brain Neoplasms (Brain Tumor) 07/2018 - 12/2017
2	Body Weight (Weight, Body) 01/2018 - 12/2008
2	Seizures (Absence Seizure) 01/2018 - 10/2015
2	Septic Shock (Toxic Shock Syndrome) 01/2017 - 01/2017
2	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2015 - 06/2015
2	Rheumatoid Arthritis 07/2015 - 07/2003
2	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2014 - 08/2010
2	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 01/2013 - 08/2003
2	Gliosis 09/2012 - 09/2009

Drug/Important Bio-Agent (IBA)

15	AntibodiesIBA 10/2020 - 10/2003
11	Natalizumab (Tysabri)FDA Link 11/2021 - 12/2008
9	Proteins (Proteins, Gene)FDA Link 10/2021 - 06/2003
9	CuprizoneIBA 01/2019 - 10/2005
8	Complement System Proteins (Complement)IBA 01/2020 - 09/2005
8	Myelin-Oligodendrocyte GlycoproteinIBA 01/2018 - 04/2006
7	laquinimodIBA 02/2019 - 10/2010
6	Fingolimod Hydrochloride (FTY720)FDA Link 01/2021 - 06/2017
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2014
5	IronIBA 01/2022 - 12/2013
5	Monoclonal AntibodiesIBA 11/2021 - 06/2003
5	AntigensIBA 09/2017 - 10/2002
5	LipopolysaccharidesIBA 01/2017 - 07/2005
4	Pharmaceutical PreparationsIBA 11/2021 - 12/2008
4	InterferonsIBA 01/2021 - 09/2013
4	CytokinesIBA 01/2020 - 10/2002
4	Peptides (Polypeptides)IBA 01/2020 - 01/2007
4	Messenger RNA (mRNA)IBA 01/2019 - 10/2002
3	Myelin ProteinsIBA 01/2020 - 05/2005
3	EnzymesIBA 10/2019 - 04/2017
3	Neuregulin-1 (Neuregulin 1)IBA 01/2019 - 09/2009
3	Dimethyl FumarateIBA 01/2019 - 03/2011
3	ChemokinesIBA 01/2019 - 12/2014
3	SteroidsIBA 01/2018 - 01/2013
3	Immunoglobulins (Immunoglobulin)IBA 01/2018 - 04/2006
3	Immunoglobulin G (IgG)IBA 10/2016 - 01/2015
3	AutoantibodiesIBA 10/2016 - 12/2006
3	Toll-Like Receptors (Toll-Like Receptor)IBA 06/2016 - 07/2011
3	FumaratesIBA 10/2015 - 03/2011
3	AutoantigensIBA 09/2010 - 12/2006
3	Interferon-betaIBA 04/2009 - 01/2002
2	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2022 - 09/2005
2	IntegrinsIBA 11/2021 - 12/2008
2	Rituximab (Mabthera)FDA Link 10/2021 - 01/2019
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021 - 01/2017
2	Viral AntigensIBA 01/2020 - 04/2016
2	Glatiramer Acetate (Copaxone)FDA Link 01/2020 - 01/2002
2	Cholecalciferol (Vitamin D3)FDA Link 12/2019 - 01/2019
2	Daclizumab (Zenapax)FDA Link 10/2019 - 01/2018
2	Glial Fibrillary Acidic ProteinIBA 01/2019 - 09/2009
2	Intravenous Immunoglobulins (IVIG)FDA Link 01/2019 - 10/2002
2	nitazoxanide (NTZ)FDA Link 01/2019 - 01/2017
2	CalciumIBA 01/2019 - 10/2003
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 07/2018 - 10/2003
2	Alemtuzumab (Campath)FDA Link 01/2018 - 01/2016
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018 - 01/2002
2	Free RadicalsIBA 04/2017 - 03/2011
2	Amyloid (Amyloid Fibrils)IBA 01/2017 - 04/2013
2	Glutamate Receptors (Glutamate Receptor)IBA 10/2016 - 10/2003
2	AcidsIBA 10/2016 - 12/2012
2	Calbindin 2IBA 08/2014 - 10/2003
2	Neuropeptide Y Receptors (Neuropeptide Y Receptor)IBA 04/2013 - 09/2010
2	activin AIBA 12/2012 - 07/2003
2	Activins (Activin)IBA 12/2012 - 07/2003
2	Myelin-Associated GlycoproteinIBA 09/2012 - 01/2003
2	ProteomeIBA 02/2012 - 04/2011
2	Neuroprotective AgentsIBA 03/2011 - 01/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2006 - 10/2002

Therapy/Procedure

23	Therapeutics 11/2021 - 01/2002
4	Plasma Exchange 01/2018 - 08/2005
3	Drug Therapy (Chemotherapy) 01/2020 - 01/2009
2	Radiotherapy 01/2020 - 01/2017
2	Immunotherapy 12/2019 - 10/2008
2	Aftercare (After-Treatment) 01/2018 - 12/2017